First national surveillance of susceptibility of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella spp. to antimicrobials in Israel

Raul Colodner; Zmira Samra; Nathan Keller; Hanna Sprecher; Colin Block; Nehama Peled; Tzilia Lazarovitch; Rita Bardenstein; Orna Schwartz-Harari; Yehuda Carmeli

doi:10.1016/j.diagmicrobio.2006.07.011

First national surveillance of susceptibility of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella spp. to antimicrobials in Israel

Raul Colodner
, Zmira Samra
, Nathan Keller
, Hanna Sprecher
, Colin Block
, Nehama Peled
, Tzilia Lazarovitch
, Rita Bardenstein
, Orna Schwartz-Harari
, Yehuda Carmeli

Research output: Contribution to journal › Article › peer-review

29 Scopus citations

Abstract

In this 1st national surveillance study, the susceptibility pattern of 1011 consecutive isolates of extended-spectrum β-lactamase (ESBL)-producing Escherichia coli and Klebsiella spp. isolated from patients hospitalized in Israel hospitals, covering 62.3% of all general hospital beds in the country, was investigated. Proportion of susceptibilities (range among institutions, MIC₅₀/MIC₉₀ in micrograms per milliliter) were to ertapenem 95.0% (88.8-100%, 0.19/0.75), imipenem 98.8% (88.8-100%, 0.25/0.38), meropenem 98.2% (90.0-100%, 0.06/0.19), piperacillin-tazobactam 59.1% (42.6-77.0%, 16/256), ciprofloxacin 17.2% (9.0-24.6%, 32/32), levofloxacin 17.8% (9.0-24.6%, 32/32), amikacin 74.5% (63.8-98.0%, 6/32), and gentamicin 19.3% (12.3-28.5%, 96/256). Coresistance, cross-resistance, and variability between institutions were high. Only carbapenems retain predicted activity against ESBL-producing E. coli and Klebsiella spp. across Israeli hospitals.

Original language	English
Pages (from-to)	201-205
Number of pages	5
Journal	Diagnostic Microbiology and Infectious Disease
Volume	57
Issue number	2
DOIs	https://doi.org/10.1016/j.diagmicrobio.2006.07.011
State	Published - Feb 2007
Externally published	Yes

Keywords

Escherichia coli
Israel
β-Lactamase

Access to Document

10.1016/j.diagmicrobio.2006.07.011

Cite this

Colodner, R., Samra, Z., Keller, N., Sprecher, H., Block, C., Peled, N., Lazarovitch, T., Bardenstein, R., Schwartz-Harari, O., & Carmeli, Y. (2007). First national surveillance of susceptibility of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella spp. to antimicrobials in Israel. Diagnostic Microbiology and Infectious Disease, 57(2), 201-205. https://doi.org/10.1016/j.diagmicrobio.2006.07.011

@article{5711caa8d4d847b187e75bd04a33bdfa,

title = "First national surveillance of susceptibility of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella spp. to antimicrobials in Israel",

abstract = "In this 1st national surveillance study, the susceptibility pattern of 1011 consecutive isolates of extended-spectrum β-lactamase (ESBL)-producing Escherichia coli and Klebsiella spp. isolated from patients hospitalized in Israel hospitals, covering 62.3\% of all general hospital beds in the country, was investigated. Proportion of susceptibilities (range among institutions, MIC50/MIC90 in micrograms per milliliter) were to ertapenem 95.0\% (88.8-100\%, 0.19/0.75), imipenem 98.8\% (88.8-100\%, 0.25/0.38), meropenem 98.2\% (90.0-100\%, 0.06/0.19), piperacillin-tazobactam 59.1\% (42.6-77.0\%, 16/256), ciprofloxacin 17.2\% (9.0-24.6\%, 32/32), levofloxacin 17.8\% (9.0-24.6\%, 32/32), amikacin 74.5\% (63.8-98.0\%, 6/32), and gentamicin 19.3\% (12.3-28.5\%, 96/256). Coresistance, cross-resistance, and variability between institutions were high. Only carbapenems retain predicted activity against ESBL-producing E. coli and Klebsiella spp. across Israeli hospitals.",

keywords = "Escherichia coli, Israel, β-Lactamase",

author = "Raul Colodner and Zmira Samra and Nathan Keller and Hanna Sprecher and Colin Block and Nehama Peled and Tzilia Lazarovitch and Rita Bardenstein and Orna Schwartz-Harari and Yehuda Carmeli",

note = "Funding Information: This study was supported by Merck \& Co., Whitehouse Station, NJ.",

year = "2007",

month = feb,

doi = "10.1016/j.diagmicrobio.2006.07.011",

language = "אנגלית",

volume = "57",

pages = "201--205",

journal = "Diagnostic Microbiology and Infectious Disease",

issn = "0732-8893",

publisher = "Elsevier Inc.",

number = "2",

}

Colodner, R, Samra, Z, Keller, N, Sprecher, H, Block, C, Peled, N, Lazarovitch, T, Bardenstein, R, Schwartz-Harari, O & Carmeli, Y 2007, 'First national surveillance of susceptibility of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella spp. to antimicrobials in Israel', Diagnostic Microbiology and Infectious Disease, vol. 57, no. 2, pp. 201-205. https://doi.org/10.1016/j.diagmicrobio.2006.07.011

TY - JOUR

T1 - First national surveillance of susceptibility of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella spp. to antimicrobials in Israel

AU - Colodner, Raul

AU - Samra, Zmira

AU - Keller, Nathan

AU - Sprecher, Hanna

AU - Block, Colin

AU - Peled, Nehama

AU - Lazarovitch, Tzilia

AU - Bardenstein, Rita

AU - Schwartz-Harari, Orna

AU - Carmeli, Yehuda

N1 - Funding Information: This study was supported by Merck & Co., Whitehouse Station, NJ.

PY - 2007/2

Y1 - 2007/2

N2 - In this 1st national surveillance study, the susceptibility pattern of 1011 consecutive isolates of extended-spectrum β-lactamase (ESBL)-producing Escherichia coli and Klebsiella spp. isolated from patients hospitalized in Israel hospitals, covering 62.3% of all general hospital beds in the country, was investigated. Proportion of susceptibilities (range among institutions, MIC50/MIC90 in micrograms per milliliter) were to ertapenem 95.0% (88.8-100%, 0.19/0.75), imipenem 98.8% (88.8-100%, 0.25/0.38), meropenem 98.2% (90.0-100%, 0.06/0.19), piperacillin-tazobactam 59.1% (42.6-77.0%, 16/256), ciprofloxacin 17.2% (9.0-24.6%, 32/32), levofloxacin 17.8% (9.0-24.6%, 32/32), amikacin 74.5% (63.8-98.0%, 6/32), and gentamicin 19.3% (12.3-28.5%, 96/256). Coresistance, cross-resistance, and variability between institutions were high. Only carbapenems retain predicted activity against ESBL-producing E. coli and Klebsiella spp. across Israeli hospitals.

AB - In this 1st national surveillance study, the susceptibility pattern of 1011 consecutive isolates of extended-spectrum β-lactamase (ESBL)-producing Escherichia coli and Klebsiella spp. isolated from patients hospitalized in Israel hospitals, covering 62.3% of all general hospital beds in the country, was investigated. Proportion of susceptibilities (range among institutions, MIC50/MIC90 in micrograms per milliliter) were to ertapenem 95.0% (88.8-100%, 0.19/0.75), imipenem 98.8% (88.8-100%, 0.25/0.38), meropenem 98.2% (90.0-100%, 0.06/0.19), piperacillin-tazobactam 59.1% (42.6-77.0%, 16/256), ciprofloxacin 17.2% (9.0-24.6%, 32/32), levofloxacin 17.8% (9.0-24.6%, 32/32), amikacin 74.5% (63.8-98.0%, 6/32), and gentamicin 19.3% (12.3-28.5%, 96/256). Coresistance, cross-resistance, and variability between institutions were high. Only carbapenems retain predicted activity against ESBL-producing E. coli and Klebsiella spp. across Israeli hospitals.

KW - Escherichia coli

KW - Israel

KW - β-Lactamase

UR - https://www.scopus.com/pages/publications/33846509415

U2 - 10.1016/j.diagmicrobio.2006.07.011

DO - 10.1016/j.diagmicrobio.2006.07.011

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 17258084

AN - SCOPUS:33846509415

SN - 0732-8893

VL - 57

SP - 201

EP - 205

JO - Diagnostic Microbiology and Infectious Disease

JF - Diagnostic Microbiology and Infectious Disease

IS - 2

ER -

First national surveillance of susceptibility of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella spp. to antimicrobials in Israel

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this